Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

ACRS Aclaris Therapeutics Inc

1,19

0,00 (0,00%)

Vor Marktöffnung

Zuletzt aktualisiert: 11:14:21

Verzögert um 15 Minuten

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more Aclaris Therapeutics Charts.

Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more Aclaris Therapeutics Charts.

News Aclaris Therapeutics Inc

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Dienstag 7 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Dienstag 7 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans
Dienstag 7 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Dienstag 7 Mai 2024 (2 Wochen vor) • GlobeNewswire Inc.

Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update
Dienstag 30 April 2024 (3 Wochen vor) • GlobeNewswire Inc.

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
Dienstag 23 April 2024 (4 Wochen vor) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 5 März 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 5 März 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 5 März 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Dienstag 27 Februar 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Dienstag 27 Februar 2024 (3 Monate vor) • Edgar (US Regulatory)

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Dienstag 27 Februar 2024 (3 Monate vor) • GlobeNewswire Inc.

Weitere Aclaris Therapeutics Inc News-Artikel

Inspired Gaming

First Financial Bankshares

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen